Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle. Ratchford JN, Brock-Simmons R, Augsburger A, Steele SU, Mohn K, Rhone M, Bo J, Costello K Int J MS Care. 2014 Summer; 16(2):92-8. PMID: 25061433. Abstract CommentRecommendBookmarkWatch